First American Bank Trims Stake in Becton, Dickinson and Company (NYSE:BDX)

First American Bank lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,520 shares of the medical instruments supplier’s stock after selling 269 shares during the quarter. First American Bank’s holdings in Becton, Dickinson and Company were worth $1,572,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $26,000. Sound Income Strategies LLC lifted its stake in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in Becton, Dickinson and Company in the 2nd quarter valued at approximately $45,000. Abound Wealth Management lifted its stake in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the period. Finally, Tributary Capital Management LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $49,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.2 %

BDX opened at $238.13 on Monday. The firm has a 50 day moving average price of $237.46 and a 200 day moving average price of $235.04. The company has a market cap of $68.82 billion, a PE ratio of 52.45, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $259.92. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.96 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on BDX shares. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI increased their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Raymond James reduced their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.